Expertise in
3
conditions

Anja J. Lorch

Zurich, ZH, CH 
Expertise in
3
conditions
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Anja Lorch practices in Zurich, Switzerland. Ms. Lorch is highly rated in 3 conditions, according to our data. Her top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Bladder Cancer, Orchiectomy, and Cystectomy.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Zurich, ZH, Switzerland
Other Locations
Chur, GR, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: Recombinant intravesical BCG, Atezolizumab, Cisplatin, Gemcitabine
Study Phase: Phase 2
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Biological
Study Drug: Nivolumab/Ipilimumab
Study Phase: Phase 2
View 8 Less Clinical Trials

87 Total Publications

Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate Cancer.
Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate Cancer.
Journal: Praxis
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lorch's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile